Who is sponsoring NCT00111410?

NCT00111410 is sponsored by Amgen.

What condition does NCT00111410 study?

NCT00111410 studies Rheumatoid Arthritis.

What drugs are being tested in NCT00111410?

Interventions: Anakinra (r-metHuIL-1ra).

What is the status of NCT00111410?

NCT00111410 is currently COMPLETED.

Last reviewed 2016-08-10 · How we verify

A Multicenter, Double-Blind, Randomized, Placebo Controlled Study to Estimate the Effect of Anakinra (r-metHuIL-1ra) on Vaccine Antibody Response in Subjects With Rheumatoid Arthritis (RA)

NCT00111410 Phase 4 COMPLETED

The purpose of this study is to estimate the effect of anakinra, 100 mg once daily (QD), on the development of an anti-tetanus antibody response in subjects with RA after vaccination with a tetanus and diphtheria toxoids injection. In addition, this study will evaluate the general safety profile of therapy with anakinra, 100 mg QD, in subjects with RA after vaccination with a tetanus and diphtheria toxoids injection.

Details

Lead sponsor	Amgen
Phase	Phase 4
Status	COMPLETED
Completion	2003-11

Conditions

Rheumatoid Arthritis

Interventions

Anakinra (r-metHuIL-1ra)

Primary outcomes

Proportion of subjects that achieve an anti-tetanus antibody response rate at study week 8 (4 weeks after the tetanus injection), based on a 4-fold titer development relative to week 4 (pre-vaccination)